Introduction {#s1}
============

Asthma is a major public health problem worldwide. The disease affects over 300 million people [@pone.0042062-Masoli1]. In developed countries, the prevalence of asthma has increased considerably over the past three decades [@pone.0042062-Wilson1]. Asthma is a complex inflammatory disorder that results from interactions between more than 100 susceptibility genes and multiple environmental factors [@pone.0042062-Umetsu1], [@pone.0042062-vonMutius1]. It is, therefore, important to identify the gene variants contributing to asthma pathogenesis. Numerous studies have focused on this field, and the cytotoxic T-lymphocyte associated antigen 4 (*CTLA-4*) gene has been extensively studied.

CTLA-4, a B7-binding protein, was initially described as a classical type I glycoprotein on the surface of activated T cells [@pone.0042062-Brunet1]. Cumulative evidence suggested that CTLA-4 may play an important role in the pathogenesis of asthma. CTLA-4 is a powerful negative regulator of T cell activation and is associated with Th cell differentiation. Oosterwegel et al. [@pone.0042062-Oosterwegel1] demonstrated that CTLA-4 was a potent and critical inhibitor of Th2 cell differentiation. Expression of CTLA-4 in Th2 cells was much higher than in Th1 cells [@pone.0042062-Alegre1]. CTLA-4 was also demonstrated to suppress the production of cytokines produced by Th2 cells [@pone.0042062-Alegre1]. A number of studies showed that administration of CTLA-4-Ig significantly ameliorated airway hyperresponsiveness (AHR), reduced the level of eosinophils in average bronchoalveolar lavage fluid and serum IgE, as well as cytokine production in murine asthma model [@pone.0042062-KeaneMyers1]--[@pone.0042062-Deurloo1]. Recently, Choi et al. [@pone.0042062-Choi1] reported that intranasal administration of Hph-1-ctCTLA-4 could significantly reduce infiltration of inflammatory cells, secretion of Th2 cytokines, serum IgE levels and AHR in a mouse model of allergic airway inflammation. Lin and co-workers demonstrated that decreased allergic inflammation by surfactant protein D was mediated by an increased expression of CTLA-4 in T cells [@pone.0042062-Lin1].

The human *CTLA-4* gene is located on chromosome 2q33.2 [@pone.0042062-Ueda1]. Several single nucleotide polymorphisms (SNPs) of the *CTLA-4* gene have been identified. Some of these studies have demonstrated a significant association of *CTLA-4* polymorphisms with atopy or asthma [@pone.0042062-Hizawa1]--[@pone.0042062-Lee1]. However, the results were not consistent in other studies [@pone.0042062-Iharaa1], [@pone.0042062-Heinzmann1].

Considering a single study may lack the power of providing a reliable conclusion, we performed a meta-analysis to investigate the relationship between *CTLA-4* gene variants and asthma. To our knowledge, this is the first meta-analysis of the association between *CTLA-4* polymorphisms and asthma susceptibility.

Methods {#s2}
=======

Publication search {#s2a}
------------------

Pubmed, EMBASE, HuGE Navigator, and Wanfang Database were searched (Last search was updated on March, 2012). The following MeSH terms were used in Pubmed: "asthma" and "polymorphism, genetic" and "CTLA 4 antigen". The search terms used in EMBASE and Wanfang Database were as follows: (asthma or asthmatic) and (cytotoxic T-lymphocyte associated antigen 4 or CTLA4 or CTLA-4 or CD152) and (polymorphism or mutation or variant). We also searched the reference list of original reports and review articles related to *CTLA-4* polymorphism and asthma risk to identify studies not included in the computerized databases.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Studies fulfilled the following criteria were included in this meta-analysis: (1) asthma diagnosed by a physician or according to asthma guidelines, (2) evaluation of the polymorphisms in *CTLA-4* gene and asthma risk performed, (3) using a case-control design, (4) genotype distributions in both asthma cases and controls should be available for estimating an odds ratio (OR) with 95% confidence interval (CI). Studies were excluded if one of the following existed: (1) not clinical studies, and (2) reviews and abstracts. For overlapping studies, only the one with the largest sample size was included. There was no language restriction.

Qualitative assessment {#s2c}
----------------------

Two authors independently assessed the quality of each study. Any disagreement was resolved by consensus. Quality assessment scores of molecular association studies of asthma were used to assess the quality of selected articles [@pone.0042062-Thakkinstian1]. This quality scoring system was based on both traditional epidemiologic considerations and genetic issues. Total scores ranged from 0 (worst) to 15 (best). Studies with quality scores ≤4 were defined as low quality studies [@pone.0042062-Li1].

Data extraction {#s2d}
---------------

Two investigators (Nie and Chen) independently reviewed full manuscripts of eligible studies, and the relevant data were extracted into predesigned data collection forms. We verified accuracy of data by comparing collection forms from each investigator. Any discrepancy was resolved by discussion or a third author (Xiu) would assess these articles. The following data were collected from each study: first author\'s name, year of publication, original country, ethnicity, age, atopic status,sample size, asthma and atopy definition, genotyping method, the polymorphisms in *CTLA-4* gene, and genotype number in cases and controls. Authors of the included studies were contacted via E-mail when additional study data were needed.

Statistical analysis {#s2e}
--------------------

When the data from at least 2 similar studies were available, meta-analysis was performed. ORs and 95% CIs were employed to assess the strength of association between SNPs in +49 A/G, −318 C/T, −1147 C/T, CT60 A/G, −1722 C/T, rs926169 and asthma risk. OR1, OR2, and OR3 were calculated for the genotypes 1) AA vs. GG (OR1), AG vs. GG (OR2), and AA vs. AG (OR3) for the +49 A/G and CT60 A/G polymorphisms, 2) CC vs. TT (OR1), CT vs. TT (OR2), and CC vs. CT (OR3) for the −318 C/T, −1147 C/T, and −1722 C/T polymorphisms, and 3) AA vs. CC (OR1), AC vs. CC (OR2), and AA vs. AC (OR3) for the rs926169, respectively. These pairwise differences were used to indicate the most appropriate genetic model as following: if OR1 = OR3≠1 and OR2 = 1, then a recessive model was suggested; if OR1 = OR2≠1 and OR3 = 1, then a dominant model was suggested; if OR2 = 1/OR3≠1 and OR1 = 1, then a complete overdominant model was suggested; if OR1\>OR2\>1 and OR1\>OR3\>1 (or OR1\<OR2\<1 and OR1\<OR3\<1), then a codominant model was suggested [@pone.0042062-Thakkinstian2]. Once the best genetic model was identified, this model was used to collapse the three genotypes into two groups (except in the case of a codominant model) and to pool the results again. A random-effects model, using the Mantel-Haenszel method, was used to calculate the pooled ORs. The statistical significance of OR was determined with *Z* test.

Departure from Hardy-Weinberg equilibrium (HWE) in controls was tested by the chi-square test. The Q statistic and the *I* ^2^ statistic were used to test for heterogeneity among the studies included in the meta-analysis. Sensitivity analyses were performed by including studies not in HWE. In addition, sensitivity analyses were also done by ethnicity and atopic status. Graphic exploration with funnel plots was used to evaluate the publication bias visually. The Begg\'s test and the Egger\'s test were used to assess publication bias statistically [@pone.0042062-Begg1], [@pone.0042062-Egger1].

All statistical tests were performed by using the Revman 5.1 software (Nordic Cochrane Center, Copenhagen, Denmark), STATA 11.0 software (Stata Corporation, College Station, TX), and SPSS 18.0 software (Chicago, IL, USA). A *P* value\<0.05 was considered statistically significant, except for tests of heterogeneity where a level of 0.10 was used.

Results {#s3}
=======

Literature search and study characteristics {#s3a}
-------------------------------------------

[**Figure 1**](#pone-0042062-g001){ref-type="fig"} outlines our selection process. Briefly, a total of 93 articles were identified after an initial search. After removing duplications, 32 articles were excluded. After reviewing the titles and abstracts, 35 articles were excluded because of abstracts, reviews, not clinical studies, or irrelevance of asthma risk. After reviewing full texts of the remaining 26 articles, 9 articles were further excluded. One article reported two cohorts [@pone.0042062-Undarmaa1], and each cohort was considered as a separate case-control study. Finally, a total of 18 case-control studies in 17 articles were identified [@pone.0042062-Hizawa1]--[@pone.0042062-Lee1], [@pone.0042062-Sohn1]--[@pone.0042062-Anantharaman1], including 6378 cases and 8674 controls. There were 11 studies on +49 A/G, 12 studies on −318 C/T, 6 studies on −1147 C/T, 5 studies on CT60 A/G, 3 studies on −1722 C/T and rs926169. There were 10 studies of Asians [@pone.0042062-Hizawa1], [@pone.0042062-Lee1], [@pone.0042062-Sohn1]--[@pone.0042062-Nakao1], [@pone.0042062-Chan1], [@pone.0042062-Qian1], [@pone.0042062-Undarmaa1], [@pone.0042062-Noguchi1], [@pone.0042062-Anantharaman1] and 6 studies of Caucasians [@pone.0042062-Howard1], [@pone.0042062-Jasek1], [@pone.0042062-Berce1], [@pone.0042062-Schubert1], [@pone.0042062-Daley1], [@pone.0042062-Sleiman1]. Five studies were performed in adults [@pone.0042062-Hizawa1]--[@pone.0042062-Lee1], [@pone.0042062-Undarmaa1], [@pone.0042062-Anantharaman1], 11 studies in children [@pone.0042062-Sohn1]--[@pone.0042062-Nakao1], [@pone.0042062-Chan1]--[@pone.0042062-Qian1], [@pone.0042062-Undarmaa1]--[@pone.0042062-Noguchi1]. Two studies included both adults and juveniles [@pone.0042062-Jasek1], [@pone.0042062-Daley1]. Five studies included only atopic asthma patients [@pone.0042062-Nakao1], [@pone.0042062-Jasek1], [@pone.0042062-Undarmaa1], [@pone.0042062-DeWan1], [@pone.0042062-Anantharaman1]. Four studies included both atopic and non-atopic asthma patients but the data for these patients could be separately extracted [@pone.0042062-Lee1],[@pone.0042062-Sohn1],[@pone.0042062-Oh1],[@pone.0042062-Berce1]. Seven studies did not offer detailed information [@pone.0042062-Hizawa1], [@pone.0042062-Howard1], [@pone.0042062-Chan1], [@pone.0042062-Schubert1]--[@pone.0042062-Daley1], [@pone.0042062-Sleiman1]. Asthma was defined with different criteria (physician\'s diagnosis, ATS diagnosis criteria, NHLBI/WHO guideline, NIH criteria, and Chinese asthma diagnosis criteria for children). Atopy was defined based on total IgE in 6 studies [@pone.0042062-Howard1], [@pone.0042062-Lee1], [@pone.0042062-Sohn1], [@pone.0042062-Nakao1], [@pone.0042062-Jasek1], [@pone.0042062-Qian1], radioallergosorbent test (RAST) in 2 studies [@pone.0042062-Hizawa1], [@pone.0042062-Nakao1], skin prick test to common aeroallergens (SPT) in 9 studies [@pone.0042062-Howard1], [@pone.0042062-Lee1], [@pone.0042062-Sohn1], [@pone.0042062-Oh1], [@pone.0042062-Jasek1], [@pone.0042062-Berce1], [@pone.0042062-Daley1], [@pone.0042062-Undarmaa1], [@pone.0042062-Anantharaman1], and allergen-specific IgE in 4 studies [@pone.0042062-Oh1], [@pone.0042062-Chan1], [@pone.0042062-Berce1], [@pone.0042062-Noguchi1]. The quality scores ranged from 5 to 12, suggesting high quality. The characteristics of each study included in this meta-analysis are presented in [**Table 1**](#pone-0042062-t001){ref-type="table"}. Genotype frequencies and HWE examination results are listed in [**Table 2**](#pone-0042062-t002){ref-type="table"}.

![Flow of study identification, inclusion, and exclusion.](pone.0042062.g001){#pone-0042062-g001}

10.1371/journal.pone.0042062.t001

###### Characteristics of the case-control studies included in meta-analysis.

![](pone.0042062.t001){#pone-0042062-t001-1}

  First authors/                                                                    Age                      Atopic                   Case   Control              Asthma                         Atopy              Quality            Genotyping                       *CTLA-4*
  -------------------------------------------- ------ ------------- ----------- ----------- ---------------------------------------- ------ --------- ------------------------------- ---------------------------- --------- ------------------------------- -------------------------------
  Nakao [@pone.0042062-Nakao1]                  2000      Japan        Asian     Children                    Atopic                   120      200        Physician\'s diagnosed            total IgE, RAST            5                PCR-RFLP                    +49 A/G, −318 C/T
  Hizawa [@pone.0042062-Hizawa1]                2001      Japan        Asian      Adults                       NA                     339      305        ATS diagnosis criteria                  RAST                12                PCR-RFLP                    +49 A/G, −318 C/T
  Howard [@pone.0042062-Howard1]                2002   Netherlands   Caucasian    Adults                       NA                     200      201         A algorithm based on              SPT, total IgE           11                PCR-RFLP                  −1147 C/T, −658 C/T,
                                                                                                                                                          ATS diagnosis criteria                                                                                    −318 C/T, +49 A/G
  Lee [@pone.0042062-Lee1]                      2002      Korea        Asian      Adults     Mixed[\*](#nt101){ref-type="table-fn"}    88      86         ATS diagnosis criteria             SPT, total IgE           11                PCR-RFLP                    +49 A/G, −318 C/T
  Schubert [@pone.0042062-Schubert1]            2006     Germany     Caucasian   Children                      NA                     231      270        Physician\'s diagnosed                   NA                  9                PCR-RFLP                    +49 A/G, −318 C/T
  Jasek [@pone.0042062-Jasek1]                  2006     Poland      Caucasian    Adults/                    Atopic                   219      102          NHLBI/WHO guideline              SPT, total IgE           11                PCR-RFLP                   −1147 C/T, +49 A/G,
                                                                                 juveniles                                                                                                                                                                              −318 C/T
  Qian [@pone.0042062-Qian1]                    2007      China        Asian     Children                      NA                      90      100       Chinese asthma diagnosis              Total IgE               7                PCR-RFLP                        −318 C/T
                                                                                                                                                           criteria for children                                                                             
  Sohn [@pone.0042062-Sohn1]                    2007      Korea        Asian     Children    Mixed[\*](#nt101){ref-type="table-fn"}   326      254        Physician\'s diagnosed             SPT, total IgE           11                PCR-RFLP                    +49 A/G, −318 C/T
  Chan [@pone.0042062-Chan1]                    2008      China        Asian     Children                      NA                     298      175        ATS diagnosis criteria         Allergen-specific IgE         9                PCR-RFLP                −1147 C/T, +49 A/G, JO30,
                                                                                                                                                                                                                                                                 CT60 A/G, JO31, JO27_1
  Daley [@pone.0042062-Daley1]                  2009    Australia    Caucasian    Adults/                      NA                     644      751       A positive answer to the                 SPT                  9                Illumina                   +49 A/G, −318 C/T,
                                                                                 juveniles                                                                question: "Has a doctor                                                      Bead Array                 −1147 C/T, CT60 A/G,
                                                                                                                                                        ever told you that you had                                                       System                    −1722C/T, rs926169,
                                                                                                                                                                 asthma?"                                                                                               rs231731
  Berce [@pone.0042062-Berce1]                  2010    Slovenia     Caucasian   Children    Mixed[\*](#nt101){ref-type="table-fn"}   102      84         ATS diagnosis criteria       Allergen-specific IgE, SPT      7                PCR-RFLP                        CT60 A/G
  Oh [@pone.0042062-Oh1]                        2010      Korea        Asian     Children    Mixed[\*](#nt101){ref-type="table-fn"}   742      238        ATS diagnosis criteria       Allergen-specific IgE, SPT     11                PCR-RFLP                         +49 A/G
  Undarmaa 1 [@pone.0042062-Undarmaa1]          2010      Japan        Asian     Children                    Atopic                   325      336             NIH criteria                       SPT                  9               TaqMan-ASA                   +49 A/G, −318 C/T
  Undarmaa 2 [@pone.0042062-Undarmaa1]          2010      Japan        Asian      Adults                     Atopic                   367      676        ATS diagnosis criteria                  SPT                  9               TaqMan-ASA                   +49 A/G, −318 C/T
  DeWan [@pone.0042062-DeWan1]                  2010       USA         Mixed     Children                    Atopic                    66      42         Physician\'s diagnosed                   NA                 11               Affymetrix             −318 C/T, −1147 C/T, CT60 A/G
                                                                                                                                                                                                                                    Genome-Wide Human        
                                                                                                                                                                                                                                      SNP Array 5.0          
  Sleiman [@pone.0042062-Sleiman1]              2010       USA       Caucasian   Children                      NA                     793     1988        Physician\'s diagnosed                   NA                 12         Illumina HH550 BeadChip           −1722C/T, rs926169
  Noguchi [@pone.0042062-Noguchi1]              2011      Japan        Asian     Children                    Mixed                    938     2376       Physician\'s diagnosed on       Allergen-specific IgE        12         Illumina HumanHap550v3            −1722C/T, rs926169
                                                                                                                                                       the basis of the NIH criteria                                          /610-Quad Genotyping BeadChip  
  Anantharaman [@pone.0042062-Anantharaman1]    2011    Singapore      Asian      Adults                     Atopic                   490      490       A positive answer to the                 SPT                 12      Illumina BeadXpress platform    −318 C/T, −1147 C/T, CT60 A/G
                                                                                                                                                       question: "Have you ever had                                               and Sequenom platform      
                                                                                                                                                         asthma?" and a doctor\'s                                                                            
                                                                                                                                                                 diagnosis                                                                                   

Data for atopic or non-atopic asthma patients could be separately extracted.

ATS, American Thoracic Society; NHLBI, The National Heart, Lung, and Blood Institute; WHO, The World Health Organization; NIH, National Institutes of Health; SPT, skin prick test to common aeroallergens; RAST, radioallergosorbent test; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; TaqMan-ASA, TaqMan allele-specific amplification method; NA, not available.

10.1371/journal.pone.0042062.t002

###### Distribution of *CTLA-4* genotype among patients and controls included in the meta-analysis.

![](pone.0042062.t002){#pone-0042062-t002-2}

  Studies               Asthma                Control          HWE
  -------------- ----- -------- ----- ------ --------- ----- -------
  +49 A/G                                                    
  Nakao           27      52     41     32      107     61    0.189
  Hizawa          40     178     121    40      140     125   0.935
  Howard          76      82     19     39      72      23    0.297
  Lee             15      24     49     8       29      49    0.238
  Schubert        98     105     28    105      127     38    0.968
  Jasek           66     101     52     33      48      21    0.645
  Sohn            45     125     156    19      103     132   0.859
  Chan            40     119     113    21      75      75    0.737
  Daley           238    290     88    291      338     98    0.992
  Oh              61     312     369    16      107     115   0.178
  Undarmaa 1      49     153     123    43      155     138   0.959
  Undarmaa 2      58     175     134   106      323     247   0.981
  −318 C/T                                                   
  Nakao           97      19      4    157      43       0    0.088
  Hizawa          265     71      3    238      65       2    0.278
  Howard          144     30      2    115      14       2    0.059
  Lee             70      16      2     67      15       4    0.022
  Jasek           172     44      3     79      22       1    0.694
  Schubert        181     47      3    214      53       3    0.889
  Qian            75      13      2     84      15       1    0.721
  Sohn            247     77      2    199      54       1    0.182
  Daley           537    100      5    616      128      7    0.902
  Undarmaa 1      253     67      5    263      68       5    0.801
  Undarmaa 2      284     78      5    512      153     11    0.911
  DeWan           58      7       1     35       6       1    0.267
  Anantharaman    350    128     12    343      134     13    0.799
  −1147 C/T                                                  
  Howard          108     46      2     97      18       2    0.295
  Jasek           146     65      8     66      31       5    0.587
  Chan            216     68      7    129      43       3    0.787
  Daley           445    181     18    500      226     25    0.931
  DeWan           52      13      1     29      12       1    0.853
  Anantharaman    335    140     15    307      162     21    0.949
  CT60 A/G                                                   
  Chan            13      97     183    6       58      109   0.611
  Berce           14      62     26     21      34      29    0.093
  Daley           191    317     132   229      369     148   0.977
  DeWan            8      31     27     4       19      19    0.810
  Anantharaman    36     193     261    21      161     308   0.994
  −1722 C/T                                                  
  Daley           551     89      4    644      102      4    0.986
  Sleiman         663    127      6    1666     308     14    0.954
  Noguchi         340    463     135   862     1131     391   0.537
  rs926169 A/C                                               
  Daley           236    307     100   282      356     111   0.937
  Sleiman         284    382     127   743      945     300   0.987
  Noguchi         135    455     342   336     1110     938   0.793

AA or CC;

AG, CT, or AC;

GG, TT or CC.

HWE, Hardy-Weinberg equilibrium.

Quantitative data synthesis {#s3b}
---------------------------

### The *CTLA-4* +49 A/G polymorphism {#s3b1}

Eleven studies determined the association between +49 A/G polymorphism and asthma [@pone.0042062-Hizawa1]--[@pone.0042062-Lee1], [@pone.0042062-Sohn1]--[@pone.0042062-Chan1], [@pone.0042062-Schubert1], [@pone.0042062-Daley1], [@pone.0042062-Undarmaa1]. Total sample sizes for asthma and control groups were 3822 and 3499, respectively. All studies in HWE were included in pooling. The estimated OR1, OR2 and OR3 were 1.18, 1.02, and 1.16, respectively ([**Table 3**](#pone-0042062-t003){ref-type="table"}). These estimates suggested a recessive genetic model, therefore AG and GG were combined and compared with AA. The pooled OR was 1.18 (95% CI 1.01--1.37, *P* = 0.04) ([**Figure 2**](#pone-0042062-g002){ref-type="fig"}). The exclusion of studies with Asians altered the significance of the result (OR = 1.12, 95% CI 0.85--1.48, *P* = 0.41). However, the exclusion of studies with Caucasians did not change the result (OR = 1.21, 95% CI 1.01--1.46, *P* = 0.04). Sensitivity analyses were also performed by atopic status. Borderline yet significant increase of asthma risk was found among the AA carriers of atopic asthma patients (OR 1.26, 95% CI 1.00--1.59, *P* = 0.05). The funnel plot was slightly asymmetrical ([**Figure 3**](#pone-0042062-g003){ref-type="fig"}). Begg\'s test and Egger\'s test indicated significant publication bias (*P* = 0.016 and *P* = 0.025, respectively).

![Meta-analysis with a random-effects model for the association between asthma risk and the *CTLA-4* +49 A/G polymorphism (AA vs. AG+GG).](pone.0042062.g002){#pone-0042062-g002}

![Funnel plot for publication bias in selection of studies on the *CTLA-4* +49 A/G polymorphism (AA vs. AG+GG).](pone.0042062.g003){#pone-0042062-g003}

10.1371/journal.pone.0042062.t003

###### Determination of the genetic effects of *CTLA-4* polymorphisms on asthma and sensitivity analyses.

![](pone.0042062.t003){#pone-0042062-t003-3}

  Polymorphisms      Study     Sample size   No. of   Test of association         Model         Heterogeneity                            
  --------------- ----------- ------------- -------- --------------------- ------------------- --------------- ------ --- ------- ------ ------
  +49 A/G                                                                                                                                
  AA vs. GG         Overall       2108        1875            12            1.18 (1.00--1.40)       1.98        0.05   R   12.78   0.31   14.0
  AG vs. GG         Overall       3008        2746            12            1.02 (0.91--1.14)       0.34        0.74   R   6.58    0.83   0.0
  AA vs. AG         Overall       2529        2377            12            1.16 (0.99--1.36)       1.89        0.06   R   14.76   0.19   25.0
  AA vs. AG+GG      Overall       3822        3499            12            1.18 (1.01--1.37)       2.07        0.04   R   15.42   0.16   29.0
  AA vs. AG+GG       Asian        2579        2266             8            1.21 (1.01--1.46)       2.01        0.04   R   7.52    0.38   7.0
  AA vs. AG+GG     Caucasian      1243        1233             4            1.12 (0.85--1.48)       0.83        0.41   R   6.77    0.08   56.0
  AA vs. AG+GG      Atopic        1954        1892             7            1.26 (1.00--1.59)       1.94        0.05   R   8.30    0.22   28.0
  −318 C/T                                                                                                                               
  CC vs. TT         Overall       2710        2903            12            0.99 (0.65--1.51)       0.04        0.97   R   4.62    0.95   0.0
  CT vs. TT         Overall        699        798             12            0.99 (0.64--1.52)       0.04        0.97   R   5.90    0.88   0.0
  CC vs. CT         Overall       3344        3610            12            1.03 (0.92--1.16)       0.52        0.61   R   5.38    0.91   0.0
  CC+CT vs. TT      Overall       3391        3657            12            0.96 (0.63--1.47)       0.18        0.86   R   4.64    0.95   0.0
  CC+CT vs. TT        HWE         3479        3743            13            1.01 (0.67--1.52)       0.03        0.98   R   5.38    0.94   0.0
  CC+CT vs. TT       Asian        2057        2361             7            0.91 (0.55--1.51)       0.36        0.72   R   4.16    0.66   0.0
  CC+CT vs. TT     Caucasian      1268        1254             4            1.06 (0.48--2.34)       0.14        0.89   R   0.29    0.96   0.0
  CC+CT vs. TT      Atopic        1793        2058             6            0.97 (0.57--1.65)       0.11        0.91   R   3.70    0.59   0.0
  −1147 C/T                                                                                                                              
  CC vs. TT         Overall       1353        1185             6            1.29 (0.87--1.91)       1.26        0.21   R   1.05    0.96   0.0
  CT vs. TT         Overall        564        549              6            1.16 (0.77--1.73)       0.70        0.48   R   1.21    0.94   0.0
  CC vs. CT         Overall       1815        1620             6            1.04 (0.81--1.34)       0.31        0.75   R   10.67   0.06   53.0
  CT60 A/G                                                                                                                               
  AA vs. GG         Overall        891        894              5            1.18 (0.80--1.74)       0.82        0.41   R   6.63    0.16   40.0
  AG vs. GG         Overall       1329        1254             5            1.20 (0.94--1.52)       1.45        0.15   R   7.01    0.14   43.0
  AA vs. AG         Overall        962        922              5            0.95 (0.63--1.45)       0.23        0.82   R   7.95    0.09   50.0
  AA+AG vs. GG      Overall       1591        1535             5            1.19 (0.94--1.49)       1.47        0.14   R   6.86    0.14   42.0
  −1722 C/T                                                                                                                              
  CC vs. TT         Overall       1699        3581             3            1.12 (0.90--1.40)       1.01        0.31   R   0.32    0.85   0.0
  CT vs. TT         Overall        824        1950             3            1.17 (0.94--1.45)       1.39        0.16   R   0.33    0.85   0.0
  CC vs. CT         Overall       2233        4713             3            0.97 (0.86--1.09)       0.54        0.59   R   0.01    0.99   0.0
  CC+CT vs. TT      Overall       2378        5122             3            1.15 (0.93--1.41)       1.32        0.19   R   0.37    0.83   0.0
  rs926169                                                                                                                               
  AA vs. CC         Overall       1244        2710             3            0.99 (0.85--1.15)       0.18        0.86   R   1.48    0.48   0.0
  AC vs. CC         Overall       1713        3760             3            1.05 (0.93--1.19)       0.74        0.46   R   1.61    0.45   0.0
  AA vs. AC         Overall       1799        3772             3            0.96 (0.85--1.09)       0.63        0.53   R   0.07    0.97   0.0
  AA+AC vs. CC      Overall       2368        5121             3            1.03 (0.91--1.17)       0.50        0.61   R   2.15    0.34   7.0

vs., versus; R, random-effects model.

### The *CTLA-4* −318 C/T polymorphism {#s3b2}

Twelve case-control studies identified an association between *CTLA-4* −318 C/T polymorphism and asthma risk [@pone.0042062-Hizawa1]--[@pone.0042062-Lee1], [@pone.0042062-Sohn1], [@pone.0042062-Nakao1], [@pone.0042062-Jasek1], [@pone.0042062-Schubert1]--[@pone.0042062-DeWan1], [@pone.0042062-Anantharaman1]. Total sample sizes for asthma and control groups were 3391 and 3657, respectively. All studies in HWE except one study [@pone.0042062-Lee1] were included in pooling. The estimated OR1, OR2 and OR3 were 0.99, 0.99, and 1.03, respectively ([**Table 3**](#pone-0042062-t003){ref-type="table"}). These estimates suggested a dominant genetic model, therefore CT and CC were combined and compared with TT. The pooled OR was 0.96 (95% CI 0.63--1.47, *P* = 0.86) ([**Figure 4**](#pone-0042062-g004){ref-type="fig"}). Sensitivity analysis was performed by including the study [@pone.0042062-Lee1] that did not observe HWE. The results were similar in showing no genetic effect (OR = 1.01, 95% CI 0.67--1.52, *P* = 0.98). Furthermore, no statistically significant results were found in sensitivity analyses conducted by ethnicity and atopic status ([**Table 3**](#pone-0042062-t003){ref-type="table"}). The funnel plot was slightly asymmetrical ([**Figure 5**](#pone-0042062-g005){ref-type="fig"}). Begg\'s test and Egger\'s test indicated significant publication bias (*P* = 0.011 and *P* = 0.049, respectively).

![Meta-analysis with a random-effects model for the association between asthma risk and the *CTLA-4* −318 C/T polymorphism (CC+CT vs. TT).](pone.0042062.g004){#pone-0042062-g004}

![Funnel plot for publication bias in selection of studies on the *CTLA-4* −318 C/T polymorphism (CC+CT vs. TT).](pone.0042062.g005){#pone-0042062-g005}

### The −1147 C/T, CT60 A/G, −1722 C/T, and rs926169 polymorphisms {#s3b3}

Six studies studied the association between −1147 C/T polymorphism and asthma risk [@pone.0042062-Howard1], [@pone.0042062-Jasek1], [@pone.0042062-Chan1], [@pone.0042062-Daley1], [@pone.0042062-DeWan1], [@pone.0042062-Anantharaman1]. Total sample sizes for asthma and control groups were 1866 and 1677, respectively. The estimated OR1, OR2 and OR3 were 1.29, 1.16 and 1.04, respectively ([**Table 3**](#pone-0042062-t003){ref-type="table"}). These estimates suggested a codominant genetic model. The pooled OR was 1.29 (95% CI 0.87--1.91, *P* = 0.21) and 1.16 (95% CI 0.77--1.73, *P* = 0.48). Only 5 studies and 3 studies were eligible for meta-analysis on CT60 A/G, −1722 C/T, and rs926169 polymorphisms. Dominant genetic models were chosen based on the estimated OR1, OR2 and OR3 of these three polymorphisms. Results from our meta-analysis demonstrated that CT60 A/G, −1722 C/T, and rs926169 polymorphisms were not risk factors for asthma. Summary of comparisons are listed in [**Table 3**](#pone-0042062-t003){ref-type="table"}.

Discussion {#s4}
==========

This meta-analysis of 17 case-control studies including 6378 cases and 8674 controls systematically evaluated the association between +49 A/G, −318 C/T, −1147 C/T, CT60 A/G, −1722 C/T, and rs926169 polymorphisms in the *CTLA-4* gene and asthma risk. We found that +49 A/G polymorphism was a modest risk factor for developing asthma in the overall study population. The results revealed that carriers of the AA homozygote had 18% increased asthma risk compared to those individuals with the G allele carriers (AG+GG). In the sensitivity analysis, we found that individuals carrying AA homozygote had increased asthma risk in Asians, but not in Caucasians. These results suggested that interactions between different ethnicities and genetic variants may contribute to asthma risk. However, there were only 4 studies on Caucasians for this polymorphism [@pone.0042062-Howard1], [@pone.0042062-Jasek1], [@pone.0042062-Schubert1], [@pone.0042062-Daley1]. It is therefore possible that the observed ethnic difference was due to chance. More studies with Caucasian population are required to validate the effect of ethnic differences on asthma risk through the +49 A/G polymorphism. In addition, significant heterogeneity was observed in the Caucasians subgroup (*I* ^2^ = 56%) but not in the Asians subgroup (*I* ^2^ = 7%). Furthermore, asthma is a complex disease. Both genetic and environmental factors affect the risk of asthma in different populations. It is possible that different asthma risks in Asians and Caucasians were due to exposure to various environmental factors. However, no reported article was performed to assess the effect of environment-*CTLA-4* interactions in different ethnicities. In the future, more studies should be designed to analyze these associations. We also carried out sensitivity analysis for atopic status. We found that atopic patients had increased asthma risk, suggesting a possibility of atopic status differences in asthma pathogenesis.

Ligers and co-workers showed that CTLA-4 cell-surface expression was significantly increased in individuals carrying the AA genotype, compared to levels in carriers of the AG and GG genotypes [@pone.0042062-Ligers1]. CTLA-4 +49 G\>A caused ^17^Ala\>^17^Thr substitution in the leading peptide of CTLA-4 [@pone.0042062-Nistic1]. ^17^Thr substitution increased binding of CTLA-4 to B7.1, causing stronger inhibition on T cell activation then CTLA-4 ^17^Ala [@pone.0042062-Sun1]. In addition, T cells with +49 GG genotype had higher activation and proliferation rates compared to those with +49 AA genotype [@pone.0042062-Sun1]. Recently, the G allele of the +49 A/G polymorphism was reported to have a strong association with autoimmune diseases [@pone.0042062-Kavvoura1]--[@pone.0042062-Miyake1]. Considering the inverse relationship between allergic diseases (Th2 dominant) and autoimmune diseases (Th1 dominant), and the role of *CTLA-4* polymorphisms in determining the Th1/Th2 balance [@pone.0042062-MuntheKaas1], it is biologically plausible that the A allele of the +49 A/G polymorphism could increase the susceptibility of asthma. Our findings and a previous study by Yang et al. [@pone.0042062-Yang1] supported this speculation. Furthermore, Jones et al. [@pone.0042062-Jones1] indicated +49 A allele was associated with infant atopic dermatitis. However, how A allele of the +49 A/G polymorphism influences asthma risk is unclear. Park et al. [@pone.0042062-Park1] reported significantly lower serum sCTLA-4 levels in Behcet\'s disease patients with the CTLA-4 +49 G allele than those in healthy controls. Serum sCTLA-4 concentrations also increased in patients with allergic asthma and after allergen inhalation in sensitized asthmatic subjects [@pone.0042062-Qin1]--[@pone.0042062-Ip1]. These data suggested that +49 A/G polymorphism could influence asthma susceptibility through affecting serum sCTLA-4 level.

Results from our meta-analysis showed the lack of associations between the −318 C/T, −1147 C/T, CT60 A/G, −1722 C/T, or rs926169 polymorphisms and asthma risk. However, these results should be interpreted with caution. Because −318 C/T was shown to be associated with asthma severity and may serve as a clinically useful marker of severe asthma [@pone.0042062-Lee1]. More studies are required to assess the associations between −1147 C/T, CT60 A/G, −1722 C/T, or rs926169 polymorphisms and asthma risk, since less than 6 case-control studies were included in this meta-analysis. A positive association between these polymorphisms and asthma could not be ruled out because studies with small sample size may have insufficient statistical power to detect a slight effect.

Publication bias and heterogeneity may influence the results of meta-analyses. In our meta-analysis, only studies indexed by the selected databases were included. Negative studies were less likely to be published in journals and be available in computerized database [@pone.0042062-Thornton1], resulting in potential overestimation of effect sizes. In this meta-analysis, Begg\'s test and Egger\'s test showed significant publication bias, thus the current results should be interpreted cautiously. In addition, there was no significant heterogeneity in most of the overall comparisons for all 4 polymorphisms. Therefore, heterogeneity did not seem to have influenced the results, suggesting the reliability of our results.

Some limitations of this meta-analysis should be considered. First, the number of available studies that could be included was moderate. Therefore, the results could be influenced by factors like random error. Second, only 7 of the 17 studies were conducted in non-Asian population. Third, the overall outcomes were based on individual unadjusted ORs, while a more precise evaluation should be adjusted by other potentially suspected factors including age, sex and lifestyle. Finally, this study could not address gene-gene and gene-environment interactions, due to insufficient information from the primary publication.

In conclusion, our meta-analysis suggested that the +49 A/G polymorphism in *CTLA-4*, but not the −318 C/T, −1147 C/T, CT60 A/G, −1722 C/T, or rs926169 polymorphisms, represented a risk factor for asthma. Future large-scale studies are still needed to validate our findings. Moreover, gene-gene and gene-environment interactions should also be considered in future studies.
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